Posttreatment MRI to Predict Pathologic Complete Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy
Toulsie Ramtohul(Université Paris Sciences et Lettres), Luc Cabel(Université de Versailles Saint-Quentin-en-Yvelines), A. Tardivon(Université Paris Sciences et Lettres), Derek Lollivier(Université Paris Sciences et Lettres), Lauren Wallaert(Institut Jean Godinot), Anne Vincent‐Salomon(Université Paris Sciences et Lettres), Thomas Gaillard(Centre Hospitalier Universitaire d'Angers), Caroline Malhaire(Université Paris Sciences et Lettres), Pierre Loap(Institut Curie), Claire Bonneau(Inserm), Caroline Nhy(Institut Curie), Diana Bello-Roufai(Hôpital René Huguenin), L. Ceugnart(Centre Oscar Lambret), Lounes Djerroudi(Memorial Sloan Kettering Cancer Center), Youlia Kirova(Université Paris Sciences et Lettres), Delphine Loirat(Institut Curie), Maxime Jin(Inserm), Audrey Mailliez(Centre Oscar Lambret), Justine Spriet(Centre Oscar Lambret), François‐Clément Bidard(Inserm)
Cited by 7
Related Papers
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
|Cancer Cell|2018|1.7k
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
|Journal of Clinical Oncology|2022|676
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
|Annals of Oncology|2021|294
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268